Evidence scope: this selected answer uses a dated FDA compounding evaluation, one ClinicalTrials.gov record and an exercise-review abstract. It is not an exhaustive trial census, a current legal-status review or a treatment or dosing guide. Registration does not independently verify that a study operated as described.

The selected sources do not establish a reliable side-effect profile for administered MOTS-c. A dated regulatory review, a trial registration and measurements of natural peptide levels answer different questions. None should be presented as a complete, current safety record.

Read the date and scope of the FDA evaluation

The FDA evaluation is dated May 11, 2026 and was prepared for the July 23-24 Pharmacy Compounding Advisory Committee meeting. It reports that its review did not identify clinical studies or human exposure information sufficient to evaluate MOTS-c-related bulk substances. This is a dated finding from that evaluation, not a timeless statement that nobody has ever received MOTS-c.

Its FAERS searches retrieved no reports for the periods described, extending through March 9, 2025. The footnote warns that the agency may not know of a compounded-product event unless it is reported. An empty search is not an observed adverse-event rate or proof of safety.

The evaluation also raises immune-response and aggregation concerns while describing insufficient data to assess those risks. These concerns are not measured frequencies of allergic reactions. The advisory background document does not determine the present legal status of every product.

A trial registration is a plan, not a result

The official NCT07505745 record read for this answer was last posted April 1, 2026. It describes a proposed randomized MOTS-c intervention in adults with prediabetes and overweight or obesity, estimated enrollment of 120 and no posted results. The registry fields are the record’s assertions; they do not independently verify study conduct or human exposure.

This listing cannot establish that 120 people enrolled or received the peptide. Nor can an unreported study plan establish an adverse-event profile, effectiveness or a safe regimen. It is inaccurate to turn either a registry listing or the absence of posted results into proof that a monitored treatment has been completed.

Natural levels and exercise are different evidence

A 2026 systematic review examined exercise and mitochondrial-derived peptides, including humanin and MOTS-c. Its abstract reports nine included studies and limited, heterogeneous evidence, particularly in humans. This is not a set of nine administered-MOTS-c safety trials. Only the abstract was read for this answer.[1]

Measuring a peptide the body produces, including a change after exercise, does not measure what happens after administering a product. A natural-level association cannot establish a replacement benefit, injection safety or a dose. The exercise review is not an exhaustive search of every human administration or pharmacokinetic study.

How to read online side-effect claims

Self-reports can raise questions, but without verified product identity, a comparison group and systematic follow-up they cannot establish how often a reaction occurs or what caused it. A count of selected forum reports is not a clinical incidence estimate. Positive and negative anecdotes both retain these limits.

For the related evidence distinction, read the MaxHuman fatigue answer, which separates natural peptide measurements from a claim about taking MOTS-c.

These selected sources do not certify an online product or self-directed regimen as safe. This answer does not offer animal-to-human dose conversion, rank other peptide products or claim that every possible human study has been checked.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It provides no treatment or dosing instructions. Consult a qualified clinician for individual medical decisions.

References

  1. Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review.. Physiology international, 2026.